SAFEGUARD
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""] The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D. For more information visit: https://clinicaltrials.gov/study/NCT07187531 Participant Eligibility Eligibility includes: -12 to 40 years old -T1D diagnosis within...

